Key product types analyzed in the report include Gene Silencing, Gene Replacement, Gene Addition, and Gene Editing, with a focus on revenue and pricing trends.

The application segments discussed encompass hospitals, research institutes, and other settings, with an analysis of market size and growth potential for each.

The market segmentation in the report is categorized by product type, application, key manufacturers, and regional categories, providing in-depth analysis for each segment.

The report includes detailed chapters on market dynamics, drivers, restraints, technological trends, and an in-depth analysis of the industrial chain associated with Adeno-Associated Virus Gene Therapy.

The findings of the report aim to assist companies in making strategic decisions based on historical data from 2020 to 2025 and forecasts extending to 2031.

The market was valued at approximately USD 1,771 million in 2024 and is anticipated to reach USD 2,889 million by 2031, reflecting a compound annual growth rate (CAGR) of 7.3%.

On March 20, 2025, Global Info Research released a comprehensive report analyzing the global Adeno-Associated Virus Gene Therapy market, projecting growth trends from 2020 to 2031.

Regional analysis within the report covers North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, assessing growth trends and economic conditions in each area.

An evaluation of the competitive landscape is provided, highlighting business strategies, revenue shares, and market positioning of leading companies in the sector.

Major manufacturers in the Adeno-Associated Virus Gene Therapy market include Creative Biolabs, Affinia Therapeutics, Spark Therapeutics, and Roche, among others.